

STRIDES PHARMA GLOBAL (UK) LIMITED
BALANCE SHEET AS AT MARCH 31, 2026

		Amount in GBP	
		31-Mar-26	31-Mar-25
A	ASSETS		
I	Non-current assets		
	(a) Financial assets		
	(i) Investments	1 24,153,205	23,376,513
	Total non-current assets	24,153,205	23,376,513
II	Current assets		
	(a) Financial assets		
	(i) Investments	2 1,698	10,265
	(ii) Trade receivables	3 142,418	137,076
	(iii) Cash and cash equivalents	4 31,244	83,964
	(b) Other current assets	5 2,660,533	112,592
	Total current assets	2,835,893	343,897
	TOTAL ASSETS	26,989,098	23,720,410
B	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity share capital	6 44,250,749	44,250,749
	(b) Reserves and surplus	7 (23,758,988)	(27,420,422)
	Total Equity	20,491,761	16,830,327
II	Liabilities		
1	Current liabilities		
	(a) Financial liabilities		
	(i) Trade payables	8 4,577	142,274
	(ii) Other financial liabilities	9 6,452,461	6,707,809
	(b) Provisions	10 40,300	40,000
	Total current liabilities	6,497,337	6,890,083
	TOTAL EQUITY AND LIABILITIES	26,989,098	23,720,410

STRIDES PHARMA GLOBAL (UK) LIMITED
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026

		Amount in GBP	
	Particulars	Note No.	31-Mar-26 31-Mar-25
1	Revenue from operations		- -
2	Other Income	11	53,502 152,320
3	Total Revenue (1+2)		53,502 152,320
4	Expenses		
	(a) Finance costs	12	1,652 810
	(b) Other expenses	13	71,222 92,900
	Total expenses		72,874 93,709
5	Profit / (Loss) before taxes (3-4)		(19,372) 58,611
6	Tax Expense:		
	(a) Current tax		- -
	Total tax expenses		- -
7	Profit / (Loss) for the year after tax		(19,372) 58,611
8	Other comprehensive income		
	Items that will not be reclassified to profit or loss		- -
9	Other comprehensive income for the year, net of tax		- -
10	Total comprehensive income for the year		(19,372) 58,611

STRIDES PHARMA GLOBAL (UK) LIMITED
Notes forming part of financial statement

Note

No.

1 Non current investments **Amount in GBP**

Particulars	31-Mar-26	31-Mar-25
Investments	24,153,205	23,376,513
Total	24,153,205	23,376,513

2 Current investments **Amount in GBP**

Particulars	31-Mar-26	31-Mar-25
Investments	1,698	10,265
Total	1,698	10,265

3 Trade receivables **Amount in GBP**

Particulars	31-Mar-26	31-Mar-25
Unsecured		
Considered good	142,418	137,076
	142,418	137,076
Less: Allowance for doubtful trade receivables		
Total	142,418	137,076

4 Cash and cash equivalents **Amount in GBP**

Particulars	31-Mar-26	31-Mar-25
Balances with banks:		
In current accounts	31,244	83,964
Total	31,244	83,964

5 Other current assets **Amount in GBP**

Particulars	31-Mar-26	31-Mar-25
Unsecured, considered good		
Loans and advances to Group entities	2,660,533	112,592
Total	2,660,533	112,592

6 Share capital **Amount in GBP**

Particulars	31-Mar-26	31-Mar-25
Issued, subscribed and fully paid-up		
Equity share capital	22,979,849	22,979,849
Preference share capital	21,270,900	21,270,900
Total	44,250,749	44,250,749

7 Reserves and surplus **Amount in GBP**

Particulars	31-Mar-26	31-Mar-25
Share Application money Pending Allotment	5,450,948	1,761,575
	5,450,948	1,761,575
FVOCI equity instruments reserve	(22,664,715)	(22,570,586)
Add: Other comprehensive income for the year	(8,567)	(94,129)
	(22,673,282)	(22,664,715)
Surplus in statement of profit and loss		
Opening balance	(6,517,282)	(6,575,893)
Add: Profit / (Loss) for the year	(19,372)	58,611
Closing balance	(6,536,654)	(6,517,282)
Total	(23,758,988)	(27,420,422)

STRIDES PHARMA GLOBAL (UK) LIMITED
Notes forming part of financial statement

Note
No.

8	Trade payables	Amount in GBP	
	Particulars	31-Mar-26	31-Mar-25
	Trade payable	4,577	142,274
	Total	4,577	142,274

9	Other Current financial Liabilities	Amount in GBP	
	Particulars	31-Mar-26	31-Mar-25
	Payable to group entities	6,452,461	6,707,809
	Total	6,452,461	6,707,809

10	Provisions	Amount in GBP	
	Particulars	31-Mar-26	31-Mar-25
	Provision for expenses	40,300	40,000
	Total	40,300	40,000

STRIDES PHARMA GLOBAL (UK) LIMITED
Notes forming part of financial statement

Note
No.

11 Other Income **Amount in GBP**

Particulars	31-Mar-26	31-Mar-25
Other Income		
Exchange fluctuation gain	(35,115)	147,995
Dividend Received	-	-
Profit on sale of asset		
Interest Income	88,617	4,325
Interest on loan to subsidiary		
Total	53,502	152,320

12 Finance cost **Amount in GBP**

Particulars	31-Mar-26	31-Mar-25
Bank charges	1,652	810
Total	1,652	810

13 Other expenses **Amount in GBP**

Particulars	31-Mar-26	31-Mar-25
Director Sitting Fess	1,200	
Labour Charges	-	900
Professional fees	70,022	92,000
Total	71,222	92,900